IA
CTIC

IFP Advisors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

IFP Advisors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2
Closed – – 4121
2018
Q3 		$0 Hold
2
– – ﹤0.01% 4183
2018
Q2 		$0 Hold
2
– – ﹤0.01% 4271
2018
Q1 		$0 Hold
2
– – ﹤0.01% 3928
2017
Q4 		$0 Sell
2
-111
-98% -$325 ﹤0.01% 4392
2017
Q3 		$0 Sell
113
-3
-3% -$10 ﹤0.01% 4401
2017
Q2 		$0 Hold
116
– – ﹤0.01% 4400
2017
Q1 		$0 Sell
116
-1
-0.9% -$5 ﹤0.01% 4335
2016
Q4 		$0 Buy
117
+3
+3% +$12 ﹤0.01% 4327
2016
Q3 		$0 Hold
114
– – ﹤0.01% 4247
2016
Q2 		$0 Buy
+114
New +$523 ﹤0.01% 4272
2016
Q1 		– Sell
-3
Closed – – 4359
2015
Q4 		$0 Buy
+3
New +$40 ﹤0.01% 3939

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IFP Advisors's CTIC Position: Q4 2018 in Review

IFP Advisors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2018, closing a stake of 2 shares.

IFP Advisors first reported a position in CTIC in Q4 2015 and held it in 11 quarters. The position peaked at $0 in Q3 2018. 75 funds tracked by Wall St. Rank hold CTIC as of Q4 2018.

  • IFP Advisors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2018 after selling out during the quarter.
  • IFP Advisors sold 2 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2018.
  • IFP Advisors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 11 quarters.
  • IFP Advisors's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q3 2018.
  • 75 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2018.

Based on IFP Advisors's 13F filing for Q4 2018, filed 23 Jan 2019.